Etomidate Induction in Hysteroscopic Surgery

Peking University

Status: Not yet enrolling

Conditions: Etomidate Induced Dose; Hysteroscopic Surgery

Treatments: Drug: etomidate; Drug: propofol

Study type: Interventional

Funder types: Other

Identifiers

NCT05520645

89476

Details and patient eligibility

About

This study intends to study the optimal dose induced by etomidate in outpatients undergoing painless hysteroscopic surgery. At present, the dosage in the user manual is 0.1-0.3mg/kg. In clinical use, it is found that 0.1mg/kg often fails to achieve sedative effect, and 0.3mg/kg is prone to muscle twitching. Therefore, three groups of doses of 0.15mg/kg, 0.2mg/kg and 0.25mg/kg are set. It is hoped that this study will provide a basis for clinical evaluation of etomidate in anesthesia induction of hysteroscopic surgery.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients to undergo hysteroscopic surgery

Exclusion criteria

Hemo-dynamically unstable patients Allergic to egg protein Patients with epilepsy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

200 participants in 4 patient groups

Eto 0.15mg/kg

Experimental group

Description:

Etomidate 0.15mg/kg for anesthesia induction

Treatment:

Drug: etomidate

Eto 0.2mg/kg

Experimental group

Description:

Etomidate 0.2mg/kg for anesthesia induction

Treatment:

Drug: etomidate

Eto 0.25mg/kg

Experimental group

Description:

Etomidate 0.25mg/kg for anesthesia induction

Treatment:

Drug: etomidate

Propofol 2mg/kg

Active Comparator group

Description:

propofol 2mg/kg for anesthesia induction

Treatment:

Drug: propofol